Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Mitchell

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Cancers|August 26, 2022
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 StatusJavier Octavio Mejía-Hernández, Dinesh Raghu, Franco Caramia, et al.
Cancers|September 9, 2023
A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature ReviewArwa Abdelmogod, Lia Papadopoulos, Stephen Riordan, et al.
Cell Death & Disease|October 19, 2021
Molecular and genomic characterisation of a panel of human anal cancer cell linesGlen R Guerra, Joseph C Kong, Rosemary M Millen, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
Annals of Surgery|December 22, 2025
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar)Alessandra Borghi, Marco Fiore, Gabriele Tiné, et al.
Nature Communications|June 19, 2026
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancerSirui Weng, Lachlan Cain, James Comben, et al.
JCO Precision Oncology|February 9, 2022
Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal CancerJoseph Cherng Huei Kong, Glen Robert Guerra, Rosemary Magdalena Millen, et al.
European Urology Oncology|December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate CancerJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Journal of Agromedicine|March 18, 2020
Gender differences in respiratory health outcomes among farming cohorts around the globe: findings from the AGRICOH consortiumJonathan Fix, Isabella Annesi-Maesano, Isabelle Baldi, et al.
The Lancet. Oncology|June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trialJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Cancers|August 26, 2022
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 StatusJavier Octavio Mejía-Hernández, Dinesh Raghu, Franco Caramia, et al.
Cancers|September 9, 2023
A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature ReviewArwa Abdelmogod, Lia Papadopoulos, Stephen Riordan, et al.
Cell Death & Disease|October 19, 2021
Molecular and genomic characterisation of a panel of human anal cancer cell linesGlen R Guerra, Joseph C Kong, Rosemary M Millen, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
Annals of Surgery|December 22, 2025
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar)Alessandra Borghi, Marco Fiore, Gabriele Tiné, et al.
Nature Communications|June 19, 2026
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancerSirui Weng, Lachlan Cain, James Comben, et al.
JCO Precision Oncology|February 9, 2022
Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal CancerJoseph Cherng Huei Kong, Glen Robert Guerra, Rosemary Magdalena Millen, et al.
European Urology Oncology|December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate CancerJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Journal of Agromedicine|March 18, 2020
Gender differences in respiratory health outcomes among farming cohorts around the globe: findings from the AGRICOH consortiumJonathan Fix, Isabella Annesi-Maesano, Isabelle Baldi, et al.
The Lancet. Oncology|June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trialJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Pageof 12